Michal Szlapka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michal Szlapka has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Harald Hausmann
Clinic for Cardiovascular Surgery, MediClin Heart Center Coswig, Coswig (Anhalt), Germany
2 shared publicationsMichael Lass
Asklepios Klinikum Harburg
2 shared publicationsOliver Natho
Asklepios Klinikum Harburg
2 shared publicationsPhilipp Peitsmeyer
Asklepios Klinikum Harburg
2 shared publicationsStefanie Halder
Asklepios Klinikum Harburg
2 shared publicationsThorsten Hanke
Asklepios Klinikum Harburg
2 shared publications
Latest Publications
- 6 August 2022
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 167 (3) , 957-964
Transcatheter mitral valve implantation versus conventional redo surgery for degenerated mitral valve prostheses and rings in a multicenter registry
- 6 August 2022
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 167 (3) , 957-964
Transcatheter mitral valve implantation versus conventional redo surgery for degenerated mitral valve prostheses and rings in a multicenter registry
- Open Access
- 24 September 2021
- Published by Wiley
Device based prevention of neurological events in coronary artery bypass patients with calcified ascending aorta.
Patients with severely calcified aorta undergoing conventional cardiac surgery are at increased risk for postoperative neurologic deficits. Implementation of cerebroprotective devices may substantially reduce or even eliminate the risk of adverse neurologic event, thus enabling surgical therapy, especially when interventional treatment cannot be considered an alternative option.
- 24 September 2021
- Published by Wiley
Open AccessDevice based prevention of neurological events in coronary artery bypass patients with calcified ascending aorta.
Patients with severely calcified aorta undergoing conventional cardiac surgery are at increased risk for postoperative neurologic deficits. Implementation of cerebroprotective devices may substantially reduce or even eliminate the risk of adverse neurologic event, thus enabling surgical therapy, especially when interventional treatment cannot be considered an alternative option.
- 21 September 2021
- Published by Wiley in Journal of Cardiac Surgery
- Vol. 36 (12) , 4770-4772
Device‐based prevention of neurological events in coronary artery bypass patients with calcified ascending aorta
Patients with severely calcified aorta undergoing conventional cardiac surgery are at increased risk for postoperative neurologic deficits. Implementation of cerebroprotective devices may substantially reduce or even eliminate the risk of the adverse neurologic events, thus enabling surgical therapy, especially when interventional treatment cannot be considered an alternative option.
- 21 September 2021
- Published by Wiley in Journal of Cardiac Surgery
- Vol. 36 (12) , 4770-4772
Device‐based prevention of neurological events in coronary artery bypass patients with calcified ascending aorta
Patients with severely calcified aorta undergoing conventional cardiac surgery are at increased risk for postoperative neurologic deficits. Implementation of cerebroprotective devices may substantially reduce or even eliminate the risk of the adverse neurologic events, thus enabling surgical therapy, especially when interventional treatment cannot be considered an alternative option.
- 10 November 2020
- Published by Hindawi Limited in Journal of Cardiac Surgery
- Vol. 36 (1) , 89-96
Unique technical challenges in patients undergoing TAVR for failed aortic homografts
Objective Surgical reoperation for aortic homograft structural valve degeneration (SVD) is a high‐risk procedure. Transcatheter aortic valve replacement (TAVR) for homograft‐SVD is an alternative to reoperation, but descriptions of implantation techniques are limited. This study compares outcome in patients undergoing into two groups by the type of previously implanted aortic valve prosthesis: TAVR for failed aortic homografts (TAVR‐H) or for stented aortic bioprostheses (TAVR‐BP). Methods From 2015 to 2017, TAVR was performed in 41 patients with SVD. Thirty‐three patients in the TAVR‐BP group (six for SVD of valved conduits), and eight patients in the TAVR‐H group. The Valve Academic Research Consortium criteria were used for outcome reporting purposes. Results The patients with TAVR‐BP had predominant prosthetic stenosis (94%, p = .002), whereas TAVR‐H individuals presented mostly with regurgitation (88%, p = <.001). Patients with TAVR‐H received: Sapien‐3 (6), Sapien‐XT (1), and CoreValve (1) devices. Low, 40% ventricular fixation in relation to homograft annulus was attempted to anchor the prosthesis on the homograft suture‐line. One patient with TAVR‐BP experienced intraoperative distal prosthesis migration and Type‐B aortic dissection, and two patients in the TAVR‐H group had late postoperative proximal device migration. In both groups, there was zero 30‐day mortality, stroke, or pacemaker implantation. Conclusions TAVR for failing aortic homografts may be a feasible and safe alternative to high‐risk surgical reintervention. Precise, 40%‐ventricular device positioning appears crucial for prevention of late paravalvular leak/late prosthesis migration and minimizing the risk of repeat surgical intervention.
- 10 November 2020
- Published by Hindawi Limited in Journal of Cardiac Surgery
- Vol. 36 (1) , 89-96
Unique technical challenges in patients undergoing TAVR for failed aortic homografts
Objective Surgical reoperation for aortic homograft structural valve degeneration (SVD) is a high‐risk procedure. Transcatheter aortic valve replacement (TAVR) for homograft‐SVD is an alternative to reoperation, but descriptions of implantation techniques are limited. This study compares outcome in patients undergoing into two groups by the type of previously implanted aortic valve prosthesis: TAVR for failed aortic homografts (TAVR‐H) or for stented aortic bioprostheses (TAVR‐BP). Methods From 2015 to 2017, TAVR was performed in 41 patients with SVD. Thirty‐three patients in the TAVR‐BP group (six for SVD of valved conduits), and eight patients in the TAVR‐H group. The Valve Academic Research Consortium criteria were used for outcome reporting purposes. Results The patients with TAVR‐BP had predominant prosthetic stenosis (94%, p = .002), whereas TAVR‐H individuals presented mostly with regurgitation (88%, p = <.001). Patients with TAVR‐H received: Sapien‐3 (6), Sapien‐XT (1), and CoreValve (1) devices. Low, 40% ventricular fixation in relation to homograft annulus was attempted to anchor the prosthesis on the homograft suture‐line. One patient with TAVR‐BP experienced intraoperative distal prosthesis migration and Type‐B aortic dissection, and two patients in the TAVR‐H group had late postoperative proximal device migration. In both groups, there was zero 30‐day mortality, stroke, or pacemaker implantation. Conclusions TAVR for failing aortic homografts may be a feasible and safe alternative to high‐risk surgical reintervention. Precise, 40%‐ventricular device positioning appears crucial for prevention of late paravalvular leak/late prosthesis migration and minimizing the risk of repeat surgical intervention.
- 31 December 2017
- Published by Georg Thieme Verlag KG in The Thoracic and Cardiovascular Surgeon
- Vol. 67 (03) , 191-202
Is 300 Seconds ACT Safe and Efficient during MiECC Procedures?
Introduction The recommended minimum activated clotting time (ACT) level for cardiopulmonary bypass (CPB) of 480 seconds originated from investigations with bubble oxygenators and uncoated extracorporeal circulation (ECC) systems. Modern minimal invasive ECC (MiECC) systems are completely closed circuits containing a membrane oxygenator and a tip-to-tip surface coating. We hypothesized that surface coating and the “closed-loop” design allow the MiECC to safely run with lower ACT levels and that an ACT level of 300 seconds can be safely applied without thromboembolic complications. The aim of this study was to investigate the potential risks during application of reduced heparin levels in patients undergoing coronary surgery. Methods In this study, 68 patients undergoing coronary artery bypass grafting with MiECC were randomized to either the study group with an ACT target of 300 seconds or the control group with an ACT of 450 seconds. All other factors of MiECC remained unchanged. Results The study group received significantly less heparin and protamine (heparin [international units] median [min–max], Red_AC: 32,800 [23,000–51,500] vs. Full_AC: 50,000 [35,000–65,000] p < 0.001; protamine [international units], Red_AC: 18,000 [10,000–35,000] vs. Full_AC: 30,000 [20,000–45,000] p < 0.001). The ACT in the study group was significantly lower at the start of MiECC (mean ± standard deviation: study group 400 ± 112 vs. control group 633 ± 177; p < 0.0001). Before termination of CPB the ACT levels were: study group 344 ± 60 versus control group 506 ± 80. In both groups, the values of the endogenous thrombin potential (ETP) decreased simultaneously. None of the study participants experienced thromboembolic complications. Conclusion Since no evidence of increased thrombin formation (ETP) was found from a laboratory standpoint, we concluded that the use of MiECC with a reduced anticoagulation strategy seems possible. This alternative anticoagulation strategy leads to significant reduction in dosages of both heparin and protamine. We can confidently move forward with investigating this anticoagulation concept. However, to establish clinical safety of ACT below 300 seconds, we need larger clinical studies.
- 31 December 2017
- Published by Georg Thieme Verlag KG in The Thoracic and Cardiovascular Surgeon
- Vol. 67 (03) , 191-202
Is 300 Seconds ACT Safe and Efficient during MiECC Procedures?
Introduction The recommended minimum activated clotting time (ACT) level for cardiopulmonary bypass (CPB) of 480 seconds originated from investigations with bubble oxygenators and uncoated extracorporeal circulation (ECC) systems. Modern minimal invasive ECC (MiECC) systems are completely closed circuits containing a membrane oxygenator and a tip-to-tip surface coating. We hypothesized that surface coating and the “closed-loop” design allow the MiECC to safely run with lower ACT levels and that an ACT level of 300 seconds can be safely applied without thromboembolic complications. The aim of this study was to investigate the potential risks during application of reduced heparin levels in patients undergoing coronary surgery. Methods In this study, 68 patients undergoing coronary artery bypass grafting with MiECC were randomized to either the study group with an ACT target of 300 seconds or the control group with an ACT of 450 seconds. All other factors of MiECC remained unchanged. Results The study group received significantly less heparin and protamine (heparin [international units] median [min–max], Red_AC: 32,800 [23,000–51,500] vs. Full_AC: 50,000 [35,000–65,000] p < 0.001; protamine [international units], Red_AC: 18,000 [10,000–35,000] vs. Full_AC: 30,000 [20,000–45,000] p < 0.001). The ACT in the study group was significantly lower at the start of MiECC (mean ± standard deviation: study group 400 ± 112 vs. control group 633 ± 177; p < 0.0001). Before termination of CPB the ACT levels were: study group 344 ± 60 versus control group 506 ± 80. In both groups, the values of the endogenous thrombin potential (ETP) decreased simultaneously. None of the study participants experienced thromboembolic complications. Conclusion Since no evidence of increased thrombin formation (ETP) was found from a laboratory standpoint, we concluded that the use of MiECC with a reduced anticoagulation strategy seems possible. This alternative anticoagulation strategy leads to significant reduction in dosages of both heparin and protamine. We can confidently move forward with investigating this anticoagulation concept. However, to establish clinical safety of ACT below 300 seconds, we need larger clinical studies.